Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. develops and commercializes fertility-control products for managing animal pest populations, with current products focused on rat and mouse populations. Its product names include ContraPest, Evolve Rat, and Evolve Mouse, which are used within pest-management programs as alternatives or complements to traditional rodent-control methods.
Company news centers on Evolve commercialization, e-commerce and direct-to-consumer sales channels, Amazon marketplace management, field-study data on rodent activity, product approvals in international markets, quarterly and annual financial results, capital runway commentary, and executive leadership or board governance updates.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced warrant exercise agreements that will generate $6.3 million in gross proceeds. The transaction involves the immediate exercise of existing warrants to purchase 1,458,872 shares at $4.15 per share.
As part of the deal, the company will issue new unregistered short-term warrants for 2,188,308 shares at an exercise price of $5.25 per share, with a purchase price of $0.125 per warrant. These new warrants will expire 15 months after the effective date of the resale registration statement. If fully exercised, the new warrants could generate additional proceeds of $11.5 million.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has scheduled its Second Quarter 2025 financial results announcement for Thursday, August 7, 2025, after market close.
The company will host a conference call at 5:00 p.m. Eastern time on the same day to discuss the results. Investors can access the live webcast through the company's Investor Relations website, with a replay available for 90 days following the presentation.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced the closing of a warrant exercise transaction that generated $4.4 million in gross proceeds. The transaction involved the exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share.
As part of the transaction, the company issued new unregistered short-term warrants to purchase an additional 1,458,872 shares at $4.15 per share, with a purchase price of $0.125 per warrant. These new warrants expire 15 months after the effective date of the resale registration statement. If fully exercised, the new warrants could generate approximately $6.0 million in additional gross proceeds. H.C. Wainwright served as the exclusive placement agent for the transaction.
The company plans to use the net proceeds for working capital and general corporate purposes.
SenesTech (NASDAQ: SNES), a fertility control solutions provider for animal pest populations, has announced warrant exercise agreements that will generate $4.4 million in gross proceeds. The transaction involves the immediate exercise of existing warrants to purchase 1,458,872 shares of common stock at $2.90 per share, with an expected closing date of July 1, 2025.
As part of the transaction, SenesTech will issue new unregistered short-term warrants to purchase an additional 1,458,872 shares at $4.15 per share, with a purchase price of $0.125 per warrant. These new warrants will be exercisable immediately and expire fifteen months after the effective date of the resale registration statement. If fully exercised, these new warrants could generate additional gross proceeds of approximately $6.0 million.
The company plans to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright is serving as the exclusive placement agent for the transaction.
SenesTech (NASDAQ: SNES) has reported successful results from major urban deployments of its Evolve™ Rat Birth Control solution in Hong Kong and San Francisco. The company's innovative approach combines fertility control with traditional rodenticide methods, demonstrating significant effectiveness in urban pest control.
In Hong Kong's high-density mixed-use building deployment, the company achieved dramatic reduction in rodent sightings and bait consumption within three months. Similar success was recorded in San Francisco, with notable decreases in rodent activity and new births. SenesTech is now preparing for a container-sized order from Hong Kong following these positive results.
SenesTech (NASDAQ: SNES) has successfully completed a nine-month field trial of Evolve™ Rat Birth Control at UC Irvine's University Hills residential community. The trial, conducted with Irvine Campus Housing Authority (ICHA), demonstrated 98% bait consumption across 267 stations, replacing traditional rodenticides with an eco-friendly solution.
The initiative, which began in September 2024, was driven by resident pressure to adopt safer pest management practices. The project supported the HOOT Group's efforts to promote owl nesting and reduce rodenticide use. Following the successful trial, ICHA is placing a multi-pallet restocking order for continued deployment and expansion.
SenesTech (NASDAQ: SNES), a company specializing in fertility control solutions for rodent population management, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference. The virtual event will take place on May 29, 2025, featuring a webcast fireside chat at 3:30 p.m. ET. The company's management will also be available for one-on-one meetings with investors throughout the conference. Interested participants can access the webcast through the conference website or register for individual meetings with management through Lytham Partners.